Is axillary lymph node clearance required in node-positive breast cancer?

Area of Science:

• Oncology
• Surgical Oncology
• Radiotherapy

Background:

• Many breast cancer patients present with clinically negative axillary nodes.
• 15-20% of these patients have metastatic disease in lymph nodes detected during sentinel node biopsy.
• Further axillary treatment (clearance or radiotherapy) is often considered for positive sentinel nodes.

Purpose of the Study:

• To review evidence for managing the axilla after a positive sentinel node biopsy.
• To discuss the rationale for systemic therapy in micrometastatic disease.
• To compare axillary radiotherapy and axillary node clearance for macrometastases.

Main Methods:

• Review of existing evidence and clinical trial data.
• Analysis of outcomes for different axillary treatment strategies.
• Evaluation of treatment-related morbidity, including lymphedema.

Main Results:

• The Z0011 trial suggests omitting further axillary treatment may be safe for patients with <3 positive sentinel nodes and no extracapsular spread.
• Micrometastatic disease in sentinel nodes warrants systemic therapy, not axillary intervention.
• Axillary irradiation for macrometastases offers comparable nodal control to axillary node clearance with reduced morbidity.

Conclusions:

• Selective omission of further axillary treatment is supported by current evidence for specific patient groups.
• Axillary radiotherapy is a viable alternative to axillary node clearance for macrometastases, with lower complication rates.
• Ongoing trials will further clarify the role of axillary treatment in low-volume sentinel node metastases.